Cognito Therapeutics to Present Clinical Data Evaluating Gamma Frequency Neuromodulation in Alzheimer’s Disease at 2022 CTAD Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)– #CTAD2022–Cognito Therapeutics, a clinical-stage company pioneering disease-modifying therapeutic interventions for neurodegenerative diseases, announced today it has been selected to present clinical data from its proprietary gamma sensory stimulation in patients with Alzheimer’s Disease, at the 2022 Clinical Trials in Alzheimer’s Disease (CTAD), held November 29 – December 2, in San Francisco, CA. “We’re excited to present data at CTAD 2022 showing our proprietary gam
Click here to view original post